Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.

Trial Details

NCT ID
NCT06767514
Phase
PHASE3
Sponsor
Summit Therapeutics
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Ivonescimab Injection
  • Pembrolizumab Injection
Locations (sample)
  • Chandler, Arizona, United States|33.30616,-111.84125
  • Phoenix, Arizona, United States|33.44838,-112.07404
  • Hot Springs, Arkansas, United States|34.5037,-93.05518
  • Jonesboro, Arkansas, United States|35.8423,-90.70428
  • Alameda, California, United States|37.77099,-122.26087

Key Eligibility Criteria

  • Age ≥ 18 years old at the time of enrollment
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0 - 1
  • Expected life expectancy ≥ 3 months
  • Metastatic (Stage IV) NSCLC

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →